[Form 4] Shattuck Labs, Inc. Insider Trading Activity

Shattuck Labs, Inc. Chief Financial Officer Andrew R. Neill reported an exercise of warrants and related share acquisition.

Rhea-AI Filing Summary

Shattuck Labs, Inc. Chief Financial Officer Andrew R. Neill reported an exercise of warrants and related share acquisition. He acquired 64,027 shares of common stock, linked to a warrant exercise covering 64,027 underlying shares at an exercise price of $1.0846 per share. Following these transactions, he directly owns 292,251 shares of common stock. No sales or dispositions were reported in this filing, and no derivative warrants remain outstanding from this grant.

Insider Trade Summary

64,027 shares exercised/converted

Exercise 2 txns

Insider Neill Andrew R

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Warrants (Right to Buy)	64,027	$0.00	$0.00
Grant/Award	Common Stock	64,027	$1.0846	$69K

Holdings After Transaction: Warrants (Right to Buy) — 0 contracts (Direct); Common Stock — 292,251 shares (Direct)

Footnotes (2)

1. F1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
2. F2. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Shattuck Labs (STTK) report for Andrew R. Neill?

Shattuck Labs reported that CFO Andrew R. Neill acquired 64,027 shares of common stock. The acquisition was tied to an exercise of warrants for 64,027 underlying shares, increasing his direct ownership position without any reported share sales.

How many Shattuck Labs (STTK) shares does the CFO hold after this Form 4?

After the reported transactions, CFO Andrew R. Neill directly holds 292,251 shares of Shattuck Labs common stock. This total reflects the addition of 64,027 shares acquired in connection with the exercise of warrants reported in the same Form 4 filing.

Did the Shattuck Labs (STTK) CFO sell any shares in this Form 4 filing?

The Form 4 shows no share sales by CFO Andrew R. Neill. The transactions are coded as acquisitions and a derivative exercise, indicating warrant exercise and resulting share ownership, with no dispositions or open-market sales reported in this filing.

What was the exercise price on the Shattuck Labs (STTK) warrants exercised?

The warrants exercised by CFO Andrew R. Neill had an exercise price of $1.0846 per share. These warrants covered 64,027 underlying shares of common stock, which were acquired and are now reflected in his direct ownership position.

Are any of the Shattuck Labs (STTK) warrants from this transaction still outstanding?

According to the Form 4 data, no warrants from this specific transaction remain outstanding. The derivative line for 64,027 warrant shares shows zero remaining following the exercise, indicating this particular warrant position was fully exercised.

What do the footnotes reveal about the origin of the Shattuck Labs (STTK) warrants?

Footnotes state the warrants came from an August 2025 private placement under a securities purchase agreement. In that deal, Andrew R. Neill received 64,027 shares and accompanying warrants, each warrant allowing purchase of up to 64,027 additional common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 08:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Neill Andrew R

(Last) (First) (Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN TEXAS 78701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/12/2026		A		64,027	A	$1.0846	292,251	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants (Right to Buy)	$1.0846	05/12/2026		M			64,027	(2)	(2)	Common Stock	64,027	(1)	0	D

Explanation of Responses:

1. On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

2. The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

	/s/ Andrew R. Neill	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)